This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this posta list of peculiar journal articles are highlighted, which may serve as conversationstarters from the medical literature. Authored by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Social events like holiday parties or kids birthday parties can be unpredictable. Sometimes you know everyone and it is a lot of fun. Sometimes you do not know many people and you are stuck trying to make conversation with new acquaintances.
Hypertension is one of the most common disease states that can lead to an increase in cardiovascular risk and other complications. Because of the risks of elevated blood pressure, we are often forced to use pharmacotherapy to reduce those risks. When a medication is started (or increased), we encounter risk in the form of adverse […] The post Hypertension Prescribing Cascade – 3 Common Examples appeared first on Med Ed 101.
By Richard A. Lewis, Senior Regulatory Device & Biologics Expert & James E. Valentine We recently published the first part of our review of FDAs draft guidance titled Frequently Asked Questions Developing Potential Cellular and Gene Therapy Products. Questions and Answers Guidance (see previous coverage here ). In this post we focus in on the draft guidance documents chemistry, manufacturing, and controls (CMC)-specific content.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
RYZ-101 is a synthetic peptide commercialized by Bristol-Myers Squibb, with a leading Phase III program in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Vanzacaftor + Deutivacaftor + Tezacaftor is a small molecule commercialized by Vertex Pharmaceuticals, with a leading Pre-Registration program in Cystic Fibrosis.
Vepdegestrant is a small molecule commercialized by Arvinas, with a leading Phase III program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
ATA-3219 is a gene-modified cell therapy commercialized by Atara Biotherapeutics, with a leading Phase I program in Diffuse Large B-Cell Lymphoma;Mantle Cell Lymphoma;Follicular Lymphoma;B-Cell Non-Hodgkin Lymphoma.
40
40
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
130 
Let's personalize your content